This funding opportunity supports the design and development of novel gene regulatory elements using a bioinformatics platform to enhance gene expression and manufacturing yields in therapeutic constructs for Stargardt disease. Funded activities include complexing constructs with proprietary ocular nanocarriers, in vivo evaluation, and manufacturing of msDNA drug substances for therapeutic development.
Eligible applicants are for-profit organizations. No further eligibility details are specified.
